Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 17/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.40 |
| ▸ | TNKS | O95271 | 1/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13041443 | 0.81 | OPRL1 (0.58) | OPRL1OPRM1OPRK1EGLN1 | |
| SCHEMBL3735180 | 0.79 | OPRL1 (0.42) | OPRL1OPRM1OPRK1EGLN1TNKS | |
| SCHEMBL3742698 | 0.78 | HDAC1 (0.44) | OPRL1OPRM1OPRK1 | |
| SCHEMBL13041512 | 0.78 | OPRL1 (0.67) | OPRL1OPRM1OPRK1 | |
| SCHEMBL3729128 | 0.74 | C5AR1 (0.45) | OPRL1OPRM1 | |
| SCHEMBL13310537 | 0.73 | EGLN1 (0.56) | OPRL1EGLN1 | |
| SCHEMBL11640576 | 0.72 | OPRL1 (0.48) | OPRL1OPRM1OPRK1 | |
| SCHEMBL13041582 | 0.70 | OPRL1 (0.52) | OPRL1OPRM1OPRK1EGLN1 | |
| SCHEMBL11640983 | 0.70 | OPRL1 (0.53) | OPRL1OPRM1OPRK1EGLN1TNKS | |
| SCHEMBL16618696 | 0.70 | OPRL1 (0.51) | OPRL1OPRM1OPRK1EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280049-A1 | ANTAGONISTS OF PGD2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280049-A1 | ANTAGONISTS OF PGD2 RECEPTORS | PTGDR2, PTGDR, LTB4R2 | OPRL1 233/4885OPRM1 610/4885OPRK1 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.